Prisma Health has developed an innovative ventilator device to quickly increase ventilator capacity for COVID-19 patients

              EVENT:                Prisma Health has developed an innovative ventilator device to quickly increase ventilator
                                     capacity for COVID-19 patients. The device has received emergency use authorization from
                                     the U.S. Food and Drug Administration.




                                    Prisma Health experts are working with national COVID-19 teams who have no more
                                     ventilator capacity and who can initiate emergency use of the prototype.  Emergency use
                                     authorization can offer critical care patients access to a medical device that has not
                                     gone through normal FDA approval; this is used when no comparable or satisfactory
                                     alternative options are available.




                                    We will be working closely with these teams during their field testing to monitor clinical
                                     outcomes.  Those field tests will determine whether the device performs as designed, per
                                     FDA guidelines.




              SPEAKERS:    
            Peter Tilkemeier, Chair of the Department of Medicine at Prisma Health-Upstate


                                    Dr. Marjorie Jenkins, Chief Academic Officer for Prisma Health in the Upstate market and
                                     Dean of the University of South Carolina School of Medicine Greenville




        WHEN:              
            Thursday, March 26, 10 a.m.




              WHERE:       
            Tune in for Webcast:



     
     
         https://www.webcaster4.com/Webcast/Page/2302/33881

CONTACT:
Deborah Fullerton, Prisma Health, 312-399-7557 (cell)
Tammie Epps, Prisma Health, 803-318-1598 (cell)
Sandy Dees, Prisma Health, 864-303-4115 (cell)

/PRNewswire -- March 25, 2020/

SOURCE Prisma Health